Glaukos (Glaukos) Valuation Rank

View and export this data going back to 2015. Start your Free Trial

What is Glaukos Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Glaukos Valuation Rank Related Terms

Thank you for viewing the detailed overview of Glaukos's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Glaukos (Glaukos) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (NYSE:GKOS) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

6GJ:Germany

Address

One Glaukos Way, Aliso Viejo, CA, USA, 92656

Website

https://www.glaukos.com

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Executives

Alex R. Thurman	officer: SVP & Chief Financial Officer	C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Joseph E Gilliam	officer: CFO, SVP Corporate Development	C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677
Thomas William Burns	director, 10 percent owner, officer: Chief Executive Officer	C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Marc Stapley	director	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Gilbert H Kliman	director	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Tomas Navratil	officer: Chief Development Officer	C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Leana Wen	director	C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Chris M. Calcaterra	officer: Chief Commercial Officer	C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Link William J Phd	director, 10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Jonathan Silverstein	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard L Harrison	officer: Treasurer, CFO & Secretary	26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Samuel D Isaly	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iii Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022